NEPG(SZ:000597) Zhong Guo Zheng Quan Bao·2025-09-28 20:45Core Viewpoint - The company emphasizes the importance of quality as the foundation of its operations and is committed to enhancing its quality management systems to drive market expansion and value creation [1][4]. Group 1: Quality Management Initiatives - The company has established a comprehensive quality control system that spans from raw material procurement to product delivery, ensuring a closed-loop quality management process [1][4]. - A special audit team has been formed to conduct in-depth on-site audits of 25 key raw material suppliers across 13 provinces, focusing on critical aspects such as raw material traceability and production processes [2]. - The company has set up a drug safety monitoring department to proactively track and manage product quality issues, transitioning from a reactive to a proactive approach [2][3]. Group 2: Compliance and Certifications - The company successfully passed a surprise inspection by the FDA with a "zero defect" score, demonstrating its commitment to maintaining high-quality standards [2][3]. - The raw material products have received multiple certifications, including BRC and ISO22000, and are exported to over 100 countries and regions [3]. - The company has achieved a 100% pass rate for audits conducted by domestic and international clients in its raw material production facilities [3]. Group 3: Cultural and Operational Enhancements - The company is fostering a culture of quality among all employees, emphasizing that quality awareness and professional capability are core competitive advantages [3][4]. - A "simulated flight inspection" mechanism has been established to conduct regular internal audits based on GMP standards, identifying system vulnerabilities and optimizing management processes [4]. - The company is committed to a "zero tolerance" policy regarding drug quality, reinforcing the idea that every product must meet the highest standards to ensure public health [4].